840 related articles for article (PubMed ID: 10397710)
21. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
[TBL] [Abstract][Full Text] [Related]
24. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
25. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow.
Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
Blood; 1999 Jul; 94(2):384-9. PubMed ID: 10397704
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
Craddock C; Szydlo RM; Dazzi F; Olavarria E; Cwynarski K; Yong A; Brookes P; de la Fuente J; Kanfer E; Apperley JF; Goldman JM
Br J Haematol; 2001 Jan; 112(1):228-36. PubMed ID: 11167809
[TBL] [Abstract][Full Text] [Related]
27. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study.
Wang Y; Liu DH; Fan ZP; Sun J; Wu XJ; Ma X; Xu LP; Liu KY; Liu QF; Wu DP; Huang XJ
Clin Transplant; 2012; 26(4):635-43. PubMed ID: 22515260
[TBL] [Abstract][Full Text] [Related]
28. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
[TBL] [Abstract][Full Text] [Related]
30. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
31. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
[TBL] [Abstract][Full Text] [Related]
32. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
34. Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Brandenburg U; Gottlieb D; Bradstock K
Leuk Lymphoma; 1998 Nov; 31(5-6):545-50. PubMed ID: 9922044
[TBL] [Abstract][Full Text] [Related]
35. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
36. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.
Marks DI; Hughes TP; Szydlo R; Kelly S; Cullis JO; Schwarer AP; Mackinnon S; Apperley J; Barrett AJ; Hows JM
Br J Haematol; 1992 Jul; 81(3):383-90. PubMed ID: 1390211
[TBL] [Abstract][Full Text] [Related]
37. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
38. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
[TBL] [Abstract][Full Text] [Related]
39. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
[TBL] [Abstract][Full Text] [Related]
40. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Basoglu S; Peceny R; Trenschel R; Ottinger H; Lollert A; Runde V; Grosse-Wilde H; Beelen DW; Schaefer UW
Blood; 2002 Feb; 99(4):1130-5. PubMed ID: 11830457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
